Home > News > Aclara BioSciences and Tokyo Metropolitan Institute
June 17th, 2004
Aclara BioSciences and Tokyo Metropolitan Institute
Abstract:
Aclara BioSciences Inc. and the Tokyo Metropolitan Institute of Medical Science (Rinshoken) announced today that they have entered into an agreement to collaborate on a study to evaluate breast cancer patient samples to validate candidate biomarkers detected with ACLARA's proprietary eTag(TM) technology. This study follows previously completed feasibility experiments on a small set of tissue samples from patients treated with Genentech's drug Herceptin(R) and chemotherapy.
Source:
Aclara BioSciences
Bookmark:
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||